U.S. PATENT NO. 9,815,827 CLAIM LISTING

No.	Limitation
1P	1. A method
1.1	for treating schizophrenia in a patient
1.2	without a clinically significant weight gain, comprising:
1.3	administering orally to the patient
1.4	(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof
1.5	at a dose of from 20 to 120 mg/day such that
1.6	the patient does not experience a clinically significant weight gain.
2P	2. The method of claim 1,
2.1	wherein (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide hydrochloride is administered.
3P	3. The method of claim 2, wherein the administering is conducted such that
3.1	the patient does not experience a clinically significant weight gain after six weeks of administration.
4P	4. The method of claim 3,
4.1	wherein the administering is conducted without concurrently administering another antipsychotic medication.
5P	5. The method of claim 2, further comprising:
5.1	detecting a weight gain after six weeks of administration.
6P	6. The method of claim 1,

No.	Limitation
6.1	wherein said patient has a BPRS score of at least 42 and wherein
6.2	the patient's BPRS score is significantly reduced from a baseline measurement prior to the administering.
7P	7. The method of claim 3,
7.1	wherein the dose is from 40 to 120 mg once daily.
8P	8. A method
8.1	for treating manic depressive psychosis in a patient
8.2	without a clinically significant weight gain, comprising:
8.3	administering orally to the patient
8.4	(1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof
8.5	at a dose of from 20 to 120 mg/day such that
8.6	the patient does not experience a clinically significant weight gain.
9P	9. The method of claim 8,
9.1	wherein (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide hydrochloride is administered.
10P	10. The method of claim 9,
10.1	wherein the administering is conducted such that the patient does not experience a clinically significant weight gain after six weeks of administration.
11P	11. The method of claim 9, further comprising:
11.1	detecting a weight gain after six weeks of administration.

No.	Limitation
12P	12. The method of claim 10,
12.1	wherein the administering is conducted without concurrently administering another antipsychotic medication.
13P	13. The method of claim 10,
13.1	wherein the dose is 20 mg once daily.
14P	14. The method of claim 10,
14.1	wherein the dose is 40 mg once daily.
15P	15. The method of claim 10,
15.1	wherein the dose is 60 mg once daily.
16P	16. The method of claim 10,
16.1	wherein the dose is 80 mg once daily.
17P	17. The method of claim 10,
17.1	wherein the dose is 120 mg once daily.
18P	18. The method of claim 9,
18.1	wherein the dose is 20 mg, 40 mg, 60 mg, 80 mg or 120 mg once daily.
19P	19. The method of claim 3,
19.1	wherein the dose is 20 mg once daily.
20P	20. The method of claim 3,
20.1	wherein the dose is 40 mg once daily.
21P	21. The method of claim 3,
21.1	wherein the dose is 60 mg once daily.

No.	Limitation
22P	22. The method of claim 3,
22.1	wherein the dose is 80 mg once daily.
23P	23. The method of claim 3,
23.1	wherein the dose is 120 mg once daily.
24P	24. The method of claim 2,
24.1	wherein the dose is 20 mg, 40 mg, 60 mg, 80 mg or 120 mg once daily.
25P	25. A method
25.1	of treating a patient with an antipsychotic
25.2	without a clinically significant weight gain in the patient, comprising:
25.3	orally administering the antipsychotic to the patient
25.4	once daily at a dose of from 20 to 120 mg such that
25.5	the patient does not experience a clinically significant weight gain,
25.6	wherein the antipsychotic is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof.
26P	26. The method of claim 25,
26.1	wherein the antipsychotic is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide hydrochloride.
27P	27. The method of claim 26,

No.	Limitation
27.1	wherein the administering is conducted such that the patient does not experience a clinically significant weight gain after six weeks of administration.
28P	28. The method of claim 26, further comprising:
28.1	detecting a weight gain after six weeks of administration.
29P	29. The method of claim 27,
29.1	wherein the method treats schizophrenia in the patient.
30P	30. The method of claim 27,
30.1	wherein the method treats manic depressive psychosis in the patient.
31P	31. The method of claim 25,
31.1	wherein the method treats the patient without the patient experiencing a weight gain.
32P	32. The method of claim 29,
32.1	wherein the administering is conducted without concurrently administering another antipsychotic medication.
33P	33. The method of claim 30,
33.1	wherein the administering is conducted without concurrently administering another antipsychotic medication.
34P	34. The method of claim 27,
34.1	wherein the dose is 20 mg.
35P	35. The method of claim 27,
35.1	wherein the dose is 40 mg.
36P	36. The method of claim 27,

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.